vs
Side-by-side financial comparison of HARTE HANKS INC (HHS) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $39.9M, roughly 1.4× HARTE HANKS INC). HARTE HANKS INC runs the higher net margin — 5.5% vs -83.0%, a 88.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -15.4%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -6.4%).
Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
HHS vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $57.3M |
| Net Profit | $2.2M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -0.3% | -82.2% |
| Net Margin | 5.5% | -83.0% |
| Revenue YoY | -15.4% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $0.30 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $39.9M | $57.3M | ||
| Q3 25 | $39.5M | $51.3M | ||
| Q2 25 | $38.6M | $48.5M | ||
| Q1 25 | $41.6M | $32.7M | ||
| Q4 24 | $47.1M | $41.8M | ||
| Q3 24 | $47.6M | $33.3M | ||
| Q2 24 | $45.0M | $29.1M | ||
| Q1 24 | $45.4M | $26.0M |
| Q4 25 | $2.2M | $-47.5M | ||
| Q3 25 | $-2.3M | $-52.9M | ||
| Q2 25 | $-335.0K | $-46.6M | ||
| Q1 25 | $-392.0K | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $142.0K | $-43.6M | ||
| Q2 24 | $-27.8M | $-32.3M | ||
| Q1 24 | $-171.0K | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -0.3% | -82.2% | ||
| Q3 25 | 1.3% | -102.6% | ||
| Q2 25 | 0.1% | -93.4% | ||
| Q1 25 | -0.1% | -143.7% | ||
| Q4 24 | -3.3% | -98.6% | ||
| Q3 24 | 4.0% | -132.0% | ||
| Q2 24 | 3.0% | -139.2% | ||
| Q1 24 | 0.8% | -538.7% |
| Q4 25 | 5.5% | -83.0% | ||
| Q3 25 | -5.8% | -103.1% | ||
| Q2 25 | -0.9% | -96.1% | ||
| Q1 25 | -0.9% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 0.3% | -131.2% | ||
| Q2 24 | -61.8% | -110.9% | ||
| Q1 24 | -0.4% | -544.4% |
| Q4 25 | $0.30 | $-0.73 | ||
| Q3 25 | $-0.31 | $-0.82 | ||
| Q2 25 | $-0.05 | $-0.75 | ||
| Q1 25 | $-0.05 | $-0.81 | ||
| Q4 24 | $-0.31 | $-0.71 | ||
| Q3 24 | $0.02 | $-0.73 | ||
| Q2 24 | $-3.84 | $-0.55 | ||
| Q1 24 | $-0.02 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.6M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.5M | $139.1M |
| Total Assets | $91.8M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | $388.9M | ||
| Q3 25 | $6.5M | $416.1M | ||
| Q2 25 | $4.8M | $291.0M | ||
| Q1 25 | $9.0M | $314.5M | ||
| Q4 24 | $9.8M | $320.6M | ||
| Q3 24 | $5.9M | $298.4M | ||
| Q2 24 | $11.0M | $319.1M | ||
| Q1 24 | $11.5M | $201.2M |
| Q4 25 | $20.5M | $139.1M | ||
| Q3 25 | $19.9M | $148.8M | ||
| Q2 25 | $22.2M | $-11.9M | ||
| Q1 25 | $21.4M | $18.9M | ||
| Q4 24 | $21.7M | $21.7M | ||
| Q3 24 | $21.0M | $11.2M | ||
| Q2 24 | $20.6M | $39.3M | ||
| Q1 24 | $20.0M | $61.6M |
| Q4 25 | $91.8M | $480.2M | ||
| Q3 25 | $92.7M | $506.9M | ||
| Q2 25 | $95.0M | $372.7M | ||
| Q1 25 | $100.6M | $386.7M | ||
| Q4 24 | $101.8M | $392.3M | ||
| Q3 24 | $108.1M | $363.6M | ||
| Q2 24 | $109.7M | $381.8M | ||
| Q1 24 | $113.4M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $737.0K | $-25.4M |
| Free Cash FlowOCF − Capex | $-686.0K | — |
| FCF MarginFCF / Revenue | -1.7% | — |
| Capex IntensityCapex / Revenue | 3.6% | — |
| Cash ConversionOCF / Net Profit | 0.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $737.0K | $-25.4M | ||
| Q3 25 | $3.2M | $-26.6M | ||
| Q2 25 | $-4.8M | $-23.3M | ||
| Q1 25 | $-818.0K | $-40.4M | ||
| Q4 24 | $4.0M | $-18.8M | ||
| Q3 24 | $-2.9M | $-25.2M | ||
| Q2 24 | $1.6M | $-29.1M | ||
| Q1 24 | $-5.7M | $-40.7M |
| Q4 25 | $-686.0K | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $-5.1M | — | ||
| Q1 25 | $-923.0K | — | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $-4.9M | — | ||
| Q2 24 | $926.0K | — | ||
| Q1 24 | $-6.2M | — |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | -13.1% | — | ||
| Q1 25 | -2.2% | — | ||
| Q4 24 | 7.3% | — | ||
| Q3 24 | -10.2% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -13.7% | — |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.2% | — |
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -20.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
RYTM
Segment breakdown not available.
